Immunovant Income Statement (2018-2026) | IMVT

Income Statement Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
18.70M21.36M29.76M31.99M28.43M37.74M42.25M51.84M50.58M47.96M48.34M66.06M75.47M97.27M94.52M93.65M101.20M114.25M98.92M142.29M
Selling, General & Administrative (Quarter)
11.18M16.29M11.52M15.24M11.95M11.88M11.78M12.42M15.40M13.84M13.21M14.82M18.81M18.47M19.78M20.17M26.02M17.51M15.44M17.27M
Other Operating Expenses (Quarter)
10.00M12.50M
Operating Expenses (Quarter)
29.89M37.65M41.27M47.23M40.38M49.61M64.03M64.26M78.48M61.80M61.55M80.88M94.28M115.74M114.30M113.83M127.22M131.76M114.36M159.55M
Operating Income (Quarter)
EBIT (Quarter)
-30.51M-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M
Non-operating items
Interest & Investment Income (Quarter)
4.07M3.57M8.93M8.38M7.18M6.07M4.59M6.89M6.34M5.60M5.33M8.06M
Other Non Operating Income (Quarter)
-0.63M-0.08M-0.11M0.04M0.35M0.79M-1.76M0.36M0.46M0.02M1.09M-2.59M0.03M0.63M-1.26M1.07M1.19M0.25M-0.05M0.80M
Non Operating Income (Quarter)
-0.63M-0.08M-0.11M0.04M0.35M0.79M-1.76M0.36M0.46M0.02M1.09M-2.59M0.03M0.63M-1.26M1.07M1.19M0.25M-0.05M0.80M
Net income details
EBT (Quarter)
-30.51M-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M
Tax Provisions (Quarter)
-0.04M-0.03M-0.01M0.35M0.26M0.39M-0.99M-0.01M0.45M-0.11M0.23M0.08M0.08M0.15M0.58M0.91M0.59M1.55M-2.86M
Profit After Tax (Quarter)
-30.47M-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M
Income from Continuing Operations (Quarter)
-30.47M-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M
Consolidated Net Income (Quarter)
-30.47M-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M
Income towards Parent Company (Quarter)
-30.47M-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M
Net Income towards Common Stockholders (Quarter)
-30.47M-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M
Additional items
EPS (Basic) (Quarter)
-0.31-0.35-0.36-0.41-0.35-0.41-0.49-0.45-0.57-0.45-0.36-0.52-0.60-0.74-0.76-0.63-0.71-0.73-0.61-0.73
EPS (Weighted Average and Diluted) (Quarter)
-0.31-0.35-0.36-0.41-0.35-0.41-0.49-0.45-0.57-0.45-0.36-0.52-0.60-0.74-0.76-0.63-0.71-0.73-0.61-0.73
Shares Outstanding (Weighted Average) (Quarter)
97.98M103.56M107.45M109.68M116.56M116.57M120.67M123.08M130.50M131.16M135.58M138.10M146.09M146.47M146.56M151.57M170.87M173.64M175.41M182.42M
Shares Outstanding (Diluted Average) (Quarter)
97.98M103.56M107.45M109.68M116.56M116.63M128.57M123.08M130.50M131.16M144.52M138.10M146.09M146.31M146.92M151.57M170.87M173.64M181.51M182.42M
EBITDA (Quarter)
-30.51M-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M
Interest Expenses (Quarter)
Shares Outstanding (Quarter)
97.98M0.01M115.11M116.48M116.52M0.01M129.26M0.01M130.57M0.01M0.01M145.58M146.20M146.57M147.20M0.01M171.07M174.53M0.01M203.94M
Tax Rate (Quarter)
0.130.080.03-0.88-0.55-0.621.640.01-0.780.21-0.31-0.09-0.07-0.14-0.55-0.76-0.47-1.421.90